logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

WCLC 2018 — Stage IV NSCLC: add-on atezolizumab prolongs survival in IMpower 132

Adding atezolizumab to chemotherapy boosts PFS, OS.